Value of American Thoracic Society guidelines in predicting infection or colonization with multidrug-resistant organisms in critically ill patients

Jianfeng Xie, Xudong Ma, Yingzi Huang, Min Mo, Fengmei Guo, Yi Yang, Haibo Qiu, Jianfeng Xie, Xudong Ma, Yingzi Huang, Min Mo, Fengmei Guo, Yi Yang, Haibo Qiu

Abstract

Background: The incidence rate of infection by multidrug-resistant organisms (MDROs) can affect the accuracy of etiological diagnosis when using American Thoracic Society (ATS) guidelines. We determined the accuracy of the ATS guidelines in predicting infection or colonization by MDROs over 18 months at a single ICU in eastern China.

Methods: This prospective observational study examined consecutive patients who were admitted to an intensive care unit (ICU) in Nanjing, China. MDROs were defined as bacteria that were resistant to at least three antimicrobial classes, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), Pseudomonas aeruginosa, Acinetobacter baumannii. Screening for MDROs was performed at ICU admission and discharge. Risk factors for infection or colonization with MDROs were recorded, and the accuracy of the ATS guidelines in predicting infection or colonization with MDROs was documented.

Results: There were 610 patients, 225 (37%) of whom were colonized or infected with MDROs at ICU admission, and this increased to 311 (51%) at discharge. At admission, the sensitivity (70.0%), specificity (31.6%), positive predictive value (38.2%), and negative predictive value (63.5%), all based on ATS guidelines for infection or colonization with MDROs were low. The negative predictive value was greater in patients from departments with MDRO infection rates of 31-40% than in patients from departments with MDRO infection rates of 30% or less and from departments with MDRO infection rates more than 40%.

Conclusion: ATS criteria were not reliable in predicting infection or colonization with MDROs in our ICU. The negative predictive value was greater in patients from departments with intermediate rates of MDRO infection than in patients from departments with low or high rates of MDRO infection.

Trial registration: ClinicalTrials.gov NCT01667991.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Proportion of patients with infection…
Figure 1. Proportion of patients with infection or colonization by an MDRO in different departments at admission (blue) and discharge (red).
Figure 2. Proportion of patients who had…
Figure 2. Proportion of patients who had ICU stays of 1–3 days, 4–7 days, and more than 7 days with infection or colonization by an MDRO at ICU admission (blue) and discharge (red).
*Significant difference (p<0.001).

References

    1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29: 1303–1310.
    1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348: 1546–1554.
    1. Davies J, Davies D (2010) Origins and evolution of antibiotic resistance. Microbiol Mol Biol Rev 74: 417–433.
    1. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, et al. (2008) NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007. Infect Control Hosp Epidemiol 29: 996–1011.
    1. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, et al. (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34: 344–353.
    1. Maragakis LL (2010) Recognition and prevention of multidrug-resistant Gram-negative bacteria in the intensive care unit. Critical Care Medicine 38: S345–S351.
    1. Peleg AY, Hooper DC (2010) Hospital-acquired infections due to gram-negative bacteria. N Engl J Med 362: 1804–1813.
    1. Arias CA, Murray BE (2009) Antibiotic-resistant bugs in the 21st century–a clinical super-challenge. N Engl J Med 360: 439–443.
    1. Teixeira PJ, Seligman R, Hertz FT, Cruz DB, Fachel JM (2007) Inadequate treatment of ventilator-associated pneumonia: risk factors and impact on outcomes. J Hosp Infect 65: 361–367.
    1. Nseir S, Deplanque X, Di Pompeo C, Diarra M, Roussel-Delvallez M, et al. (2008) Risk factors for relapse of ventilator-associated pneumonia related to nonfermenting Gram negative bacilli: a case-control study. J Infect 56: 319–325.
    1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, et al. (2006) Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock*. Critical Care Medicine 34: 1589–1596.
    1. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, et al. (2008) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 36: 296–327.
    1. American Thoracic Society (2005) Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171: 388–416.
    1. Shorr AF, Tabak YP, Killian AD, Gupta V, Liu LZ, et al. (2006) Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database*. Critical Care Medicine 34: 2588–2595.
    1. Soo Hoo GW (2005) Impact of Clinical Guidelines in the Management of Severe Hospital-Acquired Pneumonia. Chest 128: 2778–2787.
    1. Nachtigall I, Tamarkin A, Tafelski S, Deja M, Halle E, et al. (2009) Impact of adherence to standard operating procedures for pneumonia on outcome of intensive care unit patients. Crit Care Med 37: 159–166.
    1. Nseir S, Grailles G, Soury-Lavergne A, Minacori F, Alves I, et al. (2010) Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care unit admission. Clin Microbiol Infect 16: 902–908.
    1. Chastre J (2008) Evolving problems with resistant pathogens. Clin Microbiol Infect 14 Suppl 33–14.
    1. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM (1988) CDC definitions for nosocomial infections, 1988. Am J Infect Control 16: 128–140.
    1. Harris AD, McGregor JC, Johnson JA, Strauss SM, Moore AC, et al. (2007) Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 13: 1144–1149.
    1. Warren DK, Guth RM, Coopersmith CM, Merz LR, Zack JE, et al. (2007) Impact of a methicillin-resistant Staphylococcus aureus active surveillance program on contact precaution utilization in a surgical intensive care unit*. Critical Care Medicine 35: 430–434.
    1. Thomson T, Takagishi T, Parada JP, Schreckenberger P, Rekasius V, et al. (2011) Is universal screening of children for nasal methicillin-resistant Staphylococcus aureus colonization necessary on hospital admission? Infect Control Hosp Epidemiol 32: 626–627.
    1. Harbarth S, Fankhauser C, Schrenzel J, Christenson J, Gervaz P, et al. (2008) Universal screening for methicillin-resistant Staphylococcus aureus at hospital admission and nosocomial infection in surgical patients. JAMA 299: 1149–1157.
    1. Livermore DM (2009) Has the era of untreatable infections arrived? Journal of Antimicrobial Chemotherapy 64: i29–i36.
    1. Bertrand X, Dowzicky MJ (2012) Antimicrobial Susceptibility Among Gram-Negative Isolates Collected From Intensive Care Units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa Between 2004 and 2009 as Part of the Tigecycline Evaluation and Surveillance Trial. Clinical Therapeutics 34: 124–137.
    1. Zhang R, Eggleston K, Rotimi V, Zeckhauser RJ (2006) Antibiotic resistance as a global threat: evidence from China, Kuwait and the United States. Global Health 2: 6.
    1. Heddini A, Cars O, Qiang S, Tomson G (2009) Antibiotic resistance in China–a major future challenge. Lancet 373: 30.
    1. Wang L, Wang Y, Jin S, Wu Z, Chin DP, et al. (2008) Emergence and control of infectious diseases in China. Lancet 372: 1598–1605.
    1. Cao B, Zhao CJ, Yin YD, Zhao F, Song SF, et al. (2010) High Prevalence of Macrolide Resistance inMycoplasma pneumoniaeIsolates from Adult and Adolescent Patients with Respiratory Tract Infection in China. Clinical Infectious Diseases 51: 189–194.
    1. Reynolds L, McKee M (2009) Factors influencing antibiotic prescribing in China: An exploratory analysis. Health Policy 90: 32–36.
    1. Dong L, Yan H, Wang D (2011) Drug prescribing indicators in village health clinics across 10 provinces of Western China. Fam Pract 28: 63–67.
    1. Liang X, Jin C, Wang L, Wei L, Tomson G, et al. (2011) Unnecessary use of antibiotics for inpatient children with pneumonia in two counties of rural China. International Journal of Clinical Pharmacy 33: 750–754.
    1. Ewig S, Welte T, Chastre J, Torres A (2010) Rethinking the concepts of community-acquired and health-care-associated pneumonia. Lancet Infect Dis 10: 279–287.
    1. Parker CM, Kutsogiannis J, Muscedere J, Cook D, Dodek P, et al. (2008) Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. J Crit Care 23: 18–26.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren